Judy Olian Net Worth

The estimated Net Worth of Judy D. Olian is at least $5.44 Million dollars as of 13 July 2024. Ms. Olian owns over 1,800 units of United Therapeutics Corp stock worth over $2,563,537 and over the last 11 years he sold UTHR stock worth over $2,455,388. In addition, he makes $419,075 as Independent Director at United Therapeutics Corp.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Ms. Olian UTHR stock SEC Form 4 insiders trading

Judy has made over 27 trades of the United Therapeutics Corp stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 1,800 units of UTHR stock worth $623,142 on 13 July 2024.

The largest trade he's ever made was exercising 12,601 units of United Therapeutics Corp stock on 31 July 2023 worth over $4,362,340. On average, Judy trades about 2,330 units every 70 days since 2014. As of 13 July 2024 he still owns at least 7,405 units of United Therapeutics Corp stock.

You can see the complete history of Ms. Olian stock trades at the bottom of the page.

Judy Olian biography

Dr. Judy D. Olian Ph.D. serves as Independent Director of the Company. She has served as President of Quinnipiac University since July 2018. Previously, she served as dean of the UCLA Anderson School of Management and the John E. Anderson Chair in Management from 2006 to 2018. Her research and business expertise centers on aligning organizational strategies and design with human resource systems and incentives, and managing top management teams. She began her UCLA appointment after serving as dean and professor of management at the Smeal College of Business Administration at Pennsylvania State University. Earlier, she served in various faculty and executive roles at the University of Maryland and its Robert H. Smith School of Business. Ms. Olian serves or has been a member of various advisory boards (including the U.S. Studies Centre at the University of Sydney, Peking University Business School's International Advisory Board and Catalyst, a leading global think tank for women in business) and served as Chairman of the Loeb Awards for Business Journalism. Born and raised in Australia, Ms. Olian received her B.S. in Psychology from the Hebrew University, Jerusalem and her M.S. and Ph.D. in Industrial Relations from the University of Wisconsin, Madison. She was the Chairman of AACSB International, the premier thought leadership and accreditation organization for leading global business schools, and also serves on the board of directors of Ares Management, L.P., a publicly-traded global alternative asset management firm, and Mattel, Inc., a publicly-traded multinational toy manufacturing company. She has served as a United Therapeutics director since 2015.

What is the salary of Judy Olian?

As the Independent Director of United Therapeutics Corp, the total compensation of Judy Olian at United Therapeutics Corp is $419,075. There are 16 executives at United Therapeutics Corp getting paid more, with Martine Rothblatt having the highest compensation of $15,627,500.

How old is Judy Olian?

Judy Olian is 68, he's been the Independent Director of United Therapeutics Corp since 2015. There are 4 older and 16 younger executives at United Therapeutics Corp. The oldest executive at United Therapeutics Corp is Louis Sullivan, 86, who is the Independent Director.

What's Judy Olian's mailing address?

Judy's mailing address filed with the SEC is 2000 AVENUE OF THE STARS, 12TH FLOOR, LOS ANGELES, CA, 90067.

Insiders trading at United Therapeutics Corp

Over the last 20 years, insiders at United Therapeutics Corp have traded over $68,910,395 worth of United Therapeutics Corp stock and bought 229,703 units worth $13,655,671 . The most active insiders traders include Martine A Rothblatt, David Zaccardelli, and Roger Jeffs. On average, United Therapeutics Corp executives and independent directors trade stock every 3 days with the average trade being worth of $2,310,818. The most recent stock trade was executed by James Edgemond on 9 September 2024, trading 8,332 units of UTHR stock currently worth $991,341.

What does United Therapeutics Corp do?

united therapeutics corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. we currently have five approved products on the market, and a long-term mission of providing an unlimited supply of transplantable organs for those who need them! our employees can be found collaborating across the united states, europe and asia. as a group, we are relentless in our pursuit of “medicines for life” and continue to research and develop treatments for cardiovascular and pulmonary diseases, pediatric cancers, and other orphan diseases. #weareunitherians

Complete history of Ms. Olian stock trades at Mattel, United Therapeutics Corp, and Ares Management Corp

United Therapeutics Corp executives and stock owners

United Therapeutics Corp executives and other stock owners filed with the SEC include:

• Martine Rothblatt,
  Chairman of the Board, Chief Executive Officer
• Michael Benkowitz,
  President, Chief Operating Officer
• Paul Mahon,
  Executive Vice President, General Counsel, Corporate Secretary
• James Edgemond,
  Chief Financial Officer, Treasurer
• Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.,
  Founder, Chairman & CEO
• Dr. Martine A. Rothblatt,
  Founder, Chairman & CEO
• Michael I. Benkowitz,
  Pres & COO
• Paul A. Mahon,
  Exec. VP, Gen. Counsel & Corp. Sec.
• Paul A. Mahon J.D.,
  Exec. VP, Gen. Counsel & Corp. Sec.
• James C. Edgemond,
  CFO & Treasurer
• Christopher Patusky,
  Lead Independent Vice Chairman of the Board
• Christopher Causey,
  Independent Director
• Richard Giltner,
  Independent Director
• Louis Sullivan,
  Independent Director
• Tommy Thompson,
  Independent Director
• Nilda Mesa,
  Independent Director
• Judy Olian,
  Independent Director
• Katherine Klein,
  Independent Director
• Raymond Kurzweil,
  Independent Director
• Raymond Dwek,
  Independent Director
• Linda Maxwell,
  Director
• Dewey Steadman C.F.A.,
  Head of Investor Relations
• Leigh Peterson,
  VP of Product Devel.
• Gil Golden,
  Sr. VP & Chief Medical Officer
• Patrick Poisson,
  Exec. VP of Technical Operations
• Kevin T. Gray,
  Sr. VP of Strategic Operations & Logistics
• Holly Hobson,
  Associate VP of HR
• Dewey Steadman C.F.A., CFA,
  Head of Investor Relations
• Jan Malcolm,
  
• Ray Kurzweil,
  
• Roger Jeffs,
  President & COO
• Fred T Hadeed,
  EVP & CFO
• David Zaccardelli,
  EVP & Chief Operating Officer
• John Maxim Ferrari,
  CFO & Treasurer
• R Paul Gray,
  Director
• Lilly & Co Eli,
  Director, Chairman and CEO